Teva Study Examines Treatment Selection in Schizophrenia
Tel Aviv, Israel, September 18, 2026 Teva Pharmaceuticals has announced new findings from a study examining the factors that...
pharmaceutical research
Advertisement
Teva Highlights New UZEDY Data in Schizophrenia Care
Parsippany, New Jersey, September 21, 2026 Teva Pharmaceuticals has announced new real-world data for UZEDY® (risperidone) extended-release injectable suspension,...
Antengene Advances ATG-022 Into Phase III Gastric Cancer Study
Shanghai and Hong Kong, PRC, September 21, 2026 Antengene Corporation Limited has announced the dosing of the first patient...
Teva Reports New TEV-749 Olanzapine LAI Clinical Data
Tel Aviv, Israel, September18, 2026 Teva Pharmaceutical Industries Ltd. has announced new post hoc clinical data for TEV-‘749, its...
HFSA Highlights Late-Breaking Heart Failure Clinical Research
Washington, D.C., September 20, 2026 The Heart Failure Society of America (HFSA) has announced the late-breaking clinical research program...
Advertisements
Accro Bioscience Advances AC-101 in Ulcerative Colitis
New York, United States, September 20, 2026 Accro Bioscience has announced that the first patient has been dosed in...
AbbVie Reports New Real-World VRAYLAR Data in Depression
North Chicago, Illinois, September 18, 2026 AbbVie has announced new real-world data for VRAYLAR® (cariprazine) presented at Psych Congress...
Roche Opens Boston Innovation Center for CVRM Research
BASEL, Switzerland — September 17, 2026 Roche announced the grand opening of the Roche Genentech Innovation Center Boston, expanding...
Sling Therapeutics Starts Phase 3 Trial of Linsitinib
Austin, Texas, USA, September 16, 2026 Sling Therapeutics, Inc. has announced that the first patients have been dosed in...
The Braff Group Advises CCR on PhaseWell Partnership
Pittsburgh, Pennsylvania, USA, September 15, 2026 The Braff Group has announced that its client, Community Clinical Research (CCR) of...
Advertisement
